Azide-Dap(m-PEG4)-Val-Cit-PAB(m-PEG4)
Azide-Dap(m-PEG4)-Val-Cit-PAB(m-PEG4) - 10mg is backordered and will ship as soon as it is back in stock.
Sign up to be the first to know when this product is in stock
Azide-Dap(m-PEG4)-Val-Cit-PAB(m-PEG4) - 10mg is backordered and will ship as soon as it is back in stock.
SOLU-KNEX® cleavable linker features a Val-Cit dipeptide. In this product, a Azide-Dap(m-PEG4) moiety replaces the conventional maleimidocaproyl (MC) unit to enhance aqueous solubility. The azide functional group is widely utilized in bioconjugation via click chemistry to enable efficient and selective attachment of biomolecules. Additionally, m-PEG4 is attached to the commonly used self-immolative para-aminobenzyl (PAB) moiety to further increase aqueous solubility.
Derived from established ADC linker architectures, SOLU-KNEX® ADC linkers integrate solubilizing moieties—such as PEG, amine-containing groups, or polysarcosine (PSAR), to enhance aqueous solubility. Solubility and physicochemical properties can be finely tuned through selection and combination of these groups, making the linkers highly adaptable for diverse ADC and related applications. SOLU-KNEX® is a registered trademark of Tenova Pharmaceuticals, Inc. For research use only.
| Product Name | Azide-Dap(m-PEG4)-Val-Cit-PAB(m-PEG4) |
| Synonyms | |
| CAS Number | |
| Related CAS | |
| Molecular Formula | C41H70N10O15 |
| Molecular Weight | 943.066 |
| Purity (HPLC) | >= 95% |
| Solubility | DMSO, DMF |
| Shipping Conditions | Shipped on gel packs |
| Storage Conditions | Store at -20°C and protected from light |
| Shelf Life | 12 months after the date of delivery |
| Regulatory Statement | For Research Use Only |
References
(1) Lee, H. M., Abdul-Hadi, K., Appleman, V. A., Cardin, D., Dong, L., England, D., Ganno, M. L., Gershman, R., Gigstad, K., Gulavita, N., Hu, Z., Huang, J., Huang, S. C., Lok, D., Ma, L., Malley, J., Mizutani, M., Molchanova, N., Piatkov, K. I., … Abu-Yousif, A. O. (2025). Identification of a Novel Linker Enabling the Bioconjugation of a Cyclic Dinucleotide for the STING Antibody-Drug Conjugate TAK-500. Bioconjugate Chemistry, 36(11), 2423–2435. https://doi.org/10.1021/acs.bioconjchem.5c00424
(2) Yamazoe, S., Poudel, Y., Sega, E., Mukhopadhyay, A., Ramakrishnan, R., Ukairo, O., Liu, S., Akter, R., Sadanala, K., Que, K., Cheng, Q., Kotapati, S., Deshpande, M., Cox, M., Chourey, S., Gupta, A., Kempson, J., Pabbisetty, K., Kaspady, M., … Chekler, E. P. (2025). Discovery and Characterization of a First-in-Class LIV1-TLR7/8 Immunomodulatory Conjugate with Robust Myeloid Activation and Antitumor Activity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c00303
Documents
Datasheet MSDS
Citations
If you know of a paper that uses this product from Tenova Pharma, please let us know.
